|
ES2980788T3
(es)
|
2014-04-10 |
2024-10-03 |
H Lee Moffitt Cancer Ct & Res |
Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
|
|
CN107075479A
(zh)
|
2014-10-02 |
2017-08-18 |
美国卫生和人力服务部 |
分离对癌症特异性突变具有抗原特异性的t细胞的方法
|
|
EP3075389A1
(en)
*
|
2015-03-31 |
2016-10-05 |
Technische Universität München |
T cell receptors and peptides derived by mutations for the treatment of cancer
|
|
US10544392B2
(en)
|
2015-05-01 |
2020-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
EP4339287A3
(en)
|
2015-07-31 |
2024-05-22 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
|
WO2017048614A1
(en)
|
2015-09-15 |
2017-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood
|
|
US11141434B2
(en)
|
2016-07-07 |
2021-10-12 |
Iovance Biotherapeutics, Inc. |
Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof
|
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
CN110099998A
(zh)
|
2016-10-26 |
2019-08-06 |
艾欧凡斯生物治疗公司 |
冷冻保存的肿瘤浸润淋巴细胞的再刺激
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
TWI826360B
(zh)
|
2016-11-17 |
2023-12-21 |
美商艾歐凡斯生物治療公司 |
殘餘腫瘤浸潤性淋巴細胞及製備和使用彼之方法
|
|
ES3055314T3
(en)
|
2017-01-06 |
2026-02-11 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
US11254913B1
(en)
|
2017-03-29 |
2022-02-22 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
EP3602053B1
(en)
*
|
2017-03-31 |
2023-06-28 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods of isolating neoantigen-specific t cell receptor sequences
|
|
KR102920712B1
(ko)
|
2017-05-24 |
2026-01-30 |
노파르티스 아게 |
항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
|
|
TW201919662A
(zh)
|
2017-06-05 |
2019-06-01 |
美商艾歐凡斯生物治療公司 |
對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法
|
|
CN111511375A
(zh)
|
2017-06-30 |
2020-08-07 |
因提玛生物科学公司 |
用于基因治疗的腺相关病毒载体
|
|
AU2018335274B2
(en)
*
|
2017-09-20 |
2025-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HLA class II–restricted T cell receptors against mutated RAS
|
|
IL273515B2
(en)
|
2017-09-29 |
2026-03-01 |
Us Health |
T cell receptors that recognize mutated P53
|
|
JP7391015B2
(ja)
*
|
2017-09-29 |
2023-12-04 |
アメリカ合衆国 |
Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法
|
|
CN111787930B
(zh)
*
|
2017-10-06 |
2024-12-20 |
芝加哥大学 |
针对癌症特异性抗原对t淋巴细胞的筛选
|
|
JP7557367B2
(ja)
*
|
2017-11-17 |
2024-09-27 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
細針吸引及び小生検からのｔｉｌ拡大培養
|
|
WO2019112932A1
(en)
|
2017-12-04 |
2019-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of enriching cell populations for cancer-specific t cells using in vitro stimulation of memory t cells
|
|
EP3724885A2
(en)
*
|
2017-12-15 |
2020-10-21 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
EP3737743A1
(en)
|
2018-01-08 |
2020-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
CN112262212B
(zh)
*
|
2018-04-24 |
2024-07-12 |
美国卫生和人力服务部 |
使用羟基柠檬酸和/或其盐产生t细胞群体的方法
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019217753A1
(en)
*
|
2018-05-10 |
2019-11-14 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CN110857319B
(zh)
*
|
2018-08-24 |
2023-12-08 |
杭州康万达医药科技有限公司 |
一种分离的t细胞受体、其修饰的细胞、编码核酸及其应用
|
|
CN109679917B
(zh)
*
|
2018-09-30 |
2020-09-25 |
北京鼎成肽源生物技术有限公司 |
一种lrfft2细胞
|
|
CN109136284B
(zh)
*
|
2018-09-30 |
2020-12-29 |
北京鼎成肽源生物技术有限公司 |
一种afft2细胞
|
|
CN109294998B
(zh)
*
|
2018-09-30 |
2020-11-06 |
北京鼎成肽源生物技术有限公司 |
一种rff1细胞
|
|
CN110093317A
(zh)
*
|
2018-09-30 |
2019-08-06 |
北京鼎成肽源生物技术有限公司 |
一种lff2细胞的构建方法
|
|
CN109136269A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种aff细胞
|
|
CN109294983A
(zh)
*
|
2018-09-30 |
2019-02-01 |
北京鼎成肽源生物技术有限公司 |
一种lff2细胞
|
|
CN109136281A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种mrfft1细胞的构建方法
|
|
CN109136278B
(zh)
*
|
2018-09-30 |
2020-09-29 |
北京鼎成肽源生物技术有限公司 |
一种mrfft1细胞
|
|
CN110093373B
(zh)
*
|
2018-09-30 |
2021-05-07 |
北京鼎成肽源生物技术有限公司 |
一种afft2细胞的构建方法
|
|
CN109136279A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种mrfft2细胞的构建方法
|
|
CN110093316A
(zh)
*
|
2018-09-30 |
2019-08-06 |
北京鼎成肽源生物技术有限公司 |
一种aff细胞的构建方法
|
|
CN109136183A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种rff2细胞的构建方法
|
|
CN109294997B
(zh)
*
|
2018-09-30 |
2020-09-25 |
北京鼎成肽源生物技术有限公司 |
一种lrfft1细胞
|
|
CN109294982B
(zh)
*
|
2018-09-30 |
2020-11-06 |
北京鼎成肽源生物技术有限公司 |
一种rff2细胞
|
|
CN109136280A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种lrfft1细胞的构建方法
|
|
CN109295097B
(zh)
*
|
2018-09-30 |
2020-09-25 |
北京鼎成肽源生物技术有限公司 |
一种mrfft2细胞
|
|
CN109136268A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种lrff细胞的构建方法
|
|
CN109136277A
(zh)
*
|
2018-09-30 |
2019-01-04 |
北京鼎成肽源生物技术有限公司 |
一种lrfft2细胞的构建方法
|
|
US12453697B2
(en)
|
2018-11-05 |
2025-10-28 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
BR112021008549A2
(pt)
|
2018-11-05 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
|
|
CN113710270A
(zh)
|
2019-02-19 |
2021-11-26 |
迈斯特治疗公司 |
产生可用于治疗癌症的自体t细胞的方法及其组合物
|
|
AU2020231693A1
(en)
|
2019-03-04 |
2021-09-30 |
University Health Network |
T cell receptors and methods of use thereof
|
|
CN111748028A
(zh)
*
|
2019-03-29 |
2020-10-09 |
天津亨佳生物科技发展有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
CN111748027A
(zh)
*
|
2019-03-29 |
2020-10-09 |
天津亨佳生物科技发展有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
CN111748029B
(zh)
*
|
2019-03-29 |
2022-12-13 |
苏州蓝马医疗技术有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
CN111848782A
(zh)
*
|
2019-04-25 |
2020-10-30 |
天津亨佳生物科技发展有限公司 |
一种针对egfr l858r基因突变的特异性t细胞受体及其应用
|
|
CA3145196A1
(en)
*
|
2019-06-24 |
2020-12-30 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
|
|
WO2021026290A1
(en)
|
2019-08-07 |
2021-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cells having enhanced anti-tumor activity
|
|
IL293350A
(en)
|
2019-11-27 |
2022-07-01 |
Myst Therapeutics Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
CN111019959B
(zh)
*
|
2019-12-30 |
2022-09-13 |
北京立康生命科技有限公司 |
一种体外转录mRNA的核苷酸分子、呈递细胞及应用
|
|
EP4110799B1
(en)
|
2020-02-27 |
2024-11-06 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
CA3171583A1
(en)
|
2020-03-20 |
2021-09-23 |
Rami Yoseph |
Methods of isolating t cells and t-cell receptors from peripheral blood by single-cell analysis for immunotherapy
|
|
JP2023526156A
(ja)
|
2020-03-20 |
2023-06-21 |
アメリカ合衆国 |
免疫療法のためのｔ細胞及びｔ細胞受容体を単一細胞解析により腫瘍から単離する方法
|
|
EP4139440B1
(en)
|
2020-04-22 |
2026-08-19 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
WO2021222479A1
(en)
|
2020-04-28 |
2021-11-04 |
Lyell Immunopharma, Inc. |
Methods for culturing cells
|
|
CN112133372B
(zh)
*
|
2020-08-18 |
2022-06-03 |
北京臻知医学科技有限责任公司 |
抗原特异性tcr数据库的建立方法及抗原特异性tcr的评估方法
|
|
EP4211228B1
(en)
|
2020-09-08 |
2025-11-05 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
T cell phenotypes associated with response to adoptive cell therapy
|
|
CA3195019A1
(en)
|
2020-10-06 |
2022-04-14 |
Maria Fardis |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
KR102751115B1
(ko)
*
|
2020-10-20 |
2025-01-09 |
연세대학교 산학협력단 |
단일 세포 분석법을 이용한 tcr-항원의 특이성을 확인하는 방법
|
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
|
EP4314253A2
(en)
|
2021-03-25 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
US20260151484A1
(en)
*
|
2022-11-04 |
2026-06-04 |
Turnstone Biologics Corp. |
Compositions and methods for generating neo-antigen reactive tumor infiltrating lymphocytes
|
|
WO2025080865A1
(en)
|
2023-10-11 |
2025-04-17 |
Turnstone Biologics Corp. |
Combination of tumor infiltrating lymphocytes (til) and low dose radiation
|
|
US12612821B2
(en)
|
2024-04-16 |
2026-04-28 |
LuxWall, Inc. |
Vacuum insulated panel with improved thermal performance proximate edge of glass during asymmetric thermal conditions
|